Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Organogenesis Holdings (ORGO) Operating Expenses (2017 - 2025)

Historic Operating Expenses for Organogenesis Holdings (ORGO) over the last 9 years, with Q3 2025 value amounting to $130.1 million.

  • Organogenesis Holdings' Operating Expenses rose 1946.3% to $130.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $334.1 million, marking a year-over-year decrease of 1877.12%. This contributed to the annual value of $367.6 million for FY2024, which is 1701.54% up from last year.
  • Organogenesis Holdings' Operating Expenses amounted to $130.1 million in Q3 2025, which was up 1946.3% from $113.6 million recorded in Q2 2025.
  • Organogenesis Holdings' Operating Expenses' 5-year high stood at $144.1 million during Q2 2024, with a 5-year trough of $696000.0 in Q4 2024.
  • Its 5-year average for Operating Expenses is $83.7 million, with a median of $81.3 million in 2023.
  • Over the last 5 years, Organogenesis Holdings' Operating Expenses had its largest YoY gain of 7737.49% in 2024, and its largest YoY loss of 9904.85% in 2024.
  • Quarter analysis of 5 years shows Organogenesis Holdings' Operating Expenses stood at $75.5 million in 2021, then increased by 5.53% to $79.7 million in 2022, then decreased by 8.2% to $73.2 million in 2023, then plummeted by 99.05% to $696000.0 in 2024, then surged by 18597.84% to $130.1 million in 2025.
  • Its Operating Expenses stands at $130.1 million for Q3 2025, versus $113.6 million for Q2 2025 and $89.7 million for Q1 2025.